Table 1 Demographics and baseline characteristics (safety population)
Part A (n = 25) | Part B (n = 30) | |
|---|---|---|
Median age (range), years | 66 (44–87) | 56 (28–79) |
Gender, n (%) | ||
Male | 10 (40.0) | 15 (50.0) |
Female | 15 (60.0) | 15 (50.0) |
ECOG performance status, n (%) | ||
0 | 14 (56.0) | 9 (30.0) |
1 | 11 (44.0) | 21 (70.0) |
Tumour type, n (%) | ||
Melanoma | 3 (12.0) | 30 (100) |
Colon | 5 (20.0) | 0 |
Breast | 2 (8.0) | 0 |
Prostate | 2 (8.0) | 0 |
Gall bladder | 2 (8.0) | 0 |
Pancreas | 2 (8.0) | 0 |
Papillary thyroid | 2 (8.0) | 0 |
Othera | 7 (28.0) | 0 |
Tumour mutational status, n (%) | ||
BRAF-mutated/BRAF-WT | 3 (12.0)/15 (60.0)b | 23 (76.7)/7 (23.3) |
KRAS-mutated/KRAS-WT | 3 (12.0)/15 (60.0)b | Not collected in Part B |
Number of previous therapies for locally advanced or metastatic disease, n (%) | ||
0 | 3 (12.0) | 7 (23.3) |
1 | 3 (12.0) | 12 (40.0) |
2 | 7 (28.0) | 7 (23.3) |
3 | 6 (24.0) | 2 (6.7) |
4 | 3 (12.0) | 2 (6.7) |
≥5 | 3 (12.0) | 0 |
Type of prior therapy, n (%) | ||
Radiotherapy | 10 (40.0) | 15 (50.0) |
Neoadjuvant | 2 (8.0) | 0 |
Adjuvant | 8 (32.0) | 8 (26.7) |
